Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.42 EUR | 0.00% |
|
+2.31% | -15.00% |
06-01 | VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Sales forecast by analysts have been recently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.00% | 84.75M | - | ||
+20.64% | 85.53B | C+ | ||
-28.19% | 71.18B | B- | ||
-0.56% | 26.41B | C+ | ||
+1.71% | 17.32B | A- | ||
-10.31% | 17.18B | B | ||
+2.19% | 15.65B | A- | ||
+78.22% | 13.71B | C- | ||
+79.75% | 13.27B | C+ | ||
-23.86% | 13.28B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- V3V Stock
- V3V Stock
- Ratings VITA 34 AG